meng yan

Dr. meng yan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ZZZhen Zhang
Zhen Zhang
ZWZhixiang Wang
Zhixiang Wang
TLTianchen Luo
Tianchen Luo
MYmeng yan
meng yan
ADAndré Dekker
André Dekker
LZLujun Zhao
Lujun Zhao

21 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JMJintao Ma
Jintao Ma
CMChunliu Meng
Chunliu Meng
JTJia Tian
Jia Tian
KRKai Ren
Kai Ren
HJHuijun Jia
Huijun Jia
LZLujun Zhao
Lujun Zhao
Purpose: The purpose of this study was to investigate the prognostic differences between patients with small-cell lung cancer (SCLC) with different chemosensitivity to first-line chemotherapy who developed brain metastasis (BM) as the first site of progression. Methods: Patients with a BM after first-line treatment in the Tianjin Cancer Hospital were retrospectively analyzed. According to the time-free interval (TFI) between the completion of first-line chemotherapy and the onset of the BM, the patients were divided into the chemo-sensitive group (TFI ≥ 90 days, n = 145) and the chemo-resistant group (TFI < 90 days, n = 97). The survival time, which was calculated from the diagnosis of the BM, was analyzed after the onset of brain metastasis (BM-OS). Survival curves were plotted using the Kaplan–Meier method, and differences between groups were compared using the log-rank test. Results: In total, the median BM-OS was 8.4 months. The median BM-OS in the chemo-sensitive group was 8.8 months, and it was 8.0 months in the chemo-resistant group (p = 0.538). In patients without extracranial progression (n = 193), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 9.4 months and 9.7 months, respectively (p = 0.947). In patients with extracranial progression (n = 49), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 5.4 months and 4.2 months, respectively (p = 0.161). Conclusions: After the development of a BM as the first site of progression following chemotherapy in patients with SCLC, the prognosis of chemo-sensitive patients was not necessarily superior to chemo-resistant patients, especially in patients without extracranial progression.

30 October 2025 in European Radiology
Verified
Journal Article
Closed access
PDF file
MZMeng Zhou
Meng Zhou
MLMinghua Li
Minghua Li
QCQian Cao
Qian Cao
ZZZhen Zhang
Zhen Zhang
LWLeonard Wee
Leonard Wee
HLhongyang lu
hongyang lu

3 November 2026 in Cancer Research
Verified
Journal Article
Closed access
MZMengzhe Zhang
Mengzhe Zhang
ZLZekun Li
Zekun Li
ZXZengtuan Xiao
Zengtuan Xiao
SJShuai Jiang
Shuai Jiang
YDYiying Di
Yiying Di
ZZZhenfa Zhang
Zhenfa Zhang
A substantial proportion of patients with treatment-naïve lung adenocarcinoma (LUAD) exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. In this study, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in nonresponders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T-cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3–cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD. Significance: Targeting CHCHD3 activates cGAS-STING signaling to stimulate anti-tumor immunity and sensitize lung cancer to chemoimmunotherapy, highlighting the therapeutic potential of this approach to improve patient outcomes.

3 March 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JWJin Wang
Jin Wang
ZJZhaoyu Jiang
Zhaoyu Jiang
WJWenhao Ji
Wenhao Ji
HCHan Cheng
Han Cheng
ZZZhen Zhang
Zhen Zhang
XLXiaojing Lai
Xiaojing Lai
Background and purpose: Predicting overall survival (OS) for inoperable locally advanced non-small cell lung cancer (LA-NSCLC) treated with immune checkpoint inhibitors remains challenging due to heterogeneous clinical response. Furthermore, the application of advanced deep learning is hindered by limited immunotherapy datasets. This study aimed to develop a novel prognostic framework by integrating voxel-level deep radiomics derived from pretreatment imaging with a knowledge transfer strategy to accurately predict OS. Materials and methods: A total of 526 patients were respectively identified. A non-immunotherapy dataset from the RTOG 0617 clinical trial was used to pre-train a Vision-Mamba deep learning model to learn tumor characteristics within manually delineated tumor regions. Voxel-level radiomics feature maps were generated within tumors and integrated with CT images for dual-input co-training. Using the same dual-input, a cross-dataset transfer learning strategy was then used to adapt the pre-trained models to the immunotherapy context by fine-tuning. The model’s performance was evaluated using the concordance index (C-index), time-dependent area under the receiver operating characteristic curve, Kaplan-Meier survival analysis, calibration curves, and decision curve analysis. Additionally, Gradient-weighted Class Activation Mapping (Grad-CAM) was employed to suggest a possible interpretation of the model’s decision logic. Results: The proposed model demonstrated robust generalization ability. In the independent immunotherapy testing dataset, the model achieved a C-index of 0.73 (95% CI:0.63-0.82). The time-dependent AUCs for predicting 1-year and 2-year OS were 0.73 and 0.70, respectively. Calibration curves showed good agreement between predicted and observed survival probability. Stratification analysis showed distinct survival differences, with the high-risk group exhibiting significantly poorer OS compared to low-risk group (P<0.001). Conclusion: We developed a voxel-level deep radiomics framework that bridges the data gap in immunotherapy research through fine-tuning on a limited immunotherapy dataset, and subsequent validation on an independent immunotherapy testing dataset, demonstrating robust generalizability.

17 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
JWJin Wang
Jin Wang
ZJZhaoyu Jiang
Zhaoyu Jiang
WJWenhao Ji
Wenhao Ji
HCHan Cheng
Han Cheng
ZZZhen Zhang
Zhen Zhang
XLXiaojing Lai
Xiaojing Lai